At a glance
- Originator Ligand Pharmaceuticals
- Developer Proximagen
- Class Amides; Antineoplastics; Morpholines; Pyridines; Small molecules
- Mechanism of Action CXCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Glioblastoma; Solid tumours
Most Recent Events
- 29 Apr 2021 USL 311 is still in phase I/II trials for Glioblastoma, Solid tumours in USA, Spain (PO) (Ligand Pharmaceuticals pipeline, April 2021)
- 30 Jul 2020 Proximagen terminates phase-I/II clinical trials in Solid tumours and Glioblastoma (Combination therapy, Monotherapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO and IV) due to business reasons (NCT02765165)
- 01 Feb 2019 Chemical structure information added